Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the dyspnea market size evolved in recent years?

The market for dyspnea has experienced significant expansion in the last few years. Expectations are for it to progress from a value of $6.26 billion in 2024 to $6.75 billion in 2025, with a compound annual growth rate (CAGR) of 7.8%. Factors contributing to growth during the historic period include increased awareness of respiratory diseases, an upsurge in lifestyle-related causes, a rise in the elderly population, a growth in clinical trials, and increasing supportive measures from the government.

What are the predictions for the dyspnea market size in the coming years?

In the forthcoming years, the dyspnea market is predicted to experience robust growth. The market is slated to escalate to $8.97 billion by 2029, with a compound annual growth rate (CAGR) of 7.4%. The expansion during this forecast period can be credited to factors such as the rising incidences of chronic illnesses, an increasing need for personalized medical care, growing pollution levels, the escalating adoption of telemedicine, and the advancement of favorable legislation. Key trends projected in the forecast timeline include strategic partnerships, advancements in technology, the introduction of novel inhalers, advancements in personalized medicine, and specific therapeutic interventions.

Get your dyspnea market report here!

https://www.thebusinessresearchcompany.com/report/dyspnea-global-market-report

What key factors are fueling the growth of the dyspnea market?

The escalating occurrence of respiratory illnesses is projected to drive the dyspnea market’s expansion in the future. These diseases, impacting the lungs and other parts of the respiratory system, make breathing difficult and disrupt the proper exchange of oxygen. Widespread respiratory diseases encompass asthma, chronic obstructive pulmonary disease (COPD), tuberculosis (TB), amongst others. These diseases’ occurrences are spurred by elements like air pollution, tobacco usage, environmental toxic substances and climatic change. Dyspnea proves instrumental in diagnosing and managing respiratory diseases as it indicates lung functionality degradation, contributes to forming treatment plans, and helps track disease progression. For example, the National Asthma Council, a non-profit based in Australia, reported in November 2023 that Australia had 467 deaths related to asthma in 2022, including 299 women and 168 men, thus indicating a leap from the 355 deaths in 2021. Hence, the escalating occurrence of respiratory diseases is fuelling dyspnea market growth. Effect Of Rising Healthcare Expenditure On The Market

How is the global dyspnea market divided into key segments?

The dyspnea market covered in this report is segmented –

1) By Treatment Type: Supplemental Oxygen Therapy, Relaxation Therapy

2) By Drug Class: Antianxiety, Antibiotics, Anticholinergic Agents, Corticosteroids, Other Drug Classes

3) By Route Of Administration: Oral, Inhalation, Other Route Of Administrations

4) By End User: Hospitals, Homecare, Specialty Clinics, Ambulatory Services, Other End Users

Subsegments:

1) By Supplemental Oxygen Therapy: Continuous Flow Oxygen Therapy, Pulse Dose Oxygen Therapy, Oxygen Concentrators, Portable Oxygen Cylinders

2) By Relaxation Therapy: Breathing Exercises, Meditation and Mindfulness, Progressive Muscle Relaxation, Biofeedback Therapy

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21178&type=smp

Who are the key firms paving the way for growth in the dyspnea market?

Major companies operating in the dyspnea market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca, Novartis AG, GlaxoSmithKline, Amgen Inc., Viatris Inc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Amneal Pharmaceuticals LLC, Lupin Ltd, Lincare Holdings Inc, Nephron Pharmaceuticals Corporation, Rotech Healthcare Inc., Inogen Inc, Lannett Inc., Ligand Pharmaceuticals Incorporated, OMRON Healthcare Inc, Flexicare Medical Ltd, Zydus Cadila Healthcare Ltd, Advacare Pharma, Airways surgical Pvt. Ltd., Belluscura Plc

How are evolving market trends shaping dyspnea Strategies?

Key players in the dyspnea market are directing their efforts towards the innovation of new medications, particularly phosphodiesterase (PDE) inhibitors, to improve the effectiveness of treatments and provide heightened relief for individuals suffering from respiratory ailments. PDE inhibitors are drugs that inhibit the action of phosphodiesterase enzymes, leading to a rise in cyclic AMP or cyclic GMP levels in cells, which can promote vasodilation, decrease inflammation, or enhance cardiac function. For example, in May 2024, Verona Pharma Plc, a biopharmaceutical firm based in the UK, announced that it’s preparing for the expected U.S. introduction of ensifentrine, a pioneering dual phosphodiesterase (PDE) 3/4 inhibitor for COPD treatment, in Q3 2024, subject to FDA approval. Ensifentrine is a nebulized treatment for chronic obstructive pulmonary disease (COPD) and has proven to significantly cut exacerbation rates and boost dyspnea in Phase III clinical trials. The firm has raised $650 million in funding to back the commercial launch of the drug and its continued development, such as an intended Phase II trial for a fixed-dose combination with glycopyrrolate as a maintenance therapy for patients living with COPD.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21178

What regions are contributing significantly to the growth of the dyspnea market?

North America was the largest region in the dyspnea market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dyspnea market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Swine Feed Minerals Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/multiple-myeloma-global-market-report

Multiple Myeloma Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/multiple-myeloma-drugs-global-market-report

Acute Pancreatitis Global Market Report 2025

https://thebusinessresearchcompany.com/report/acute-pancreatitis-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: